Table 1.
Patients’ characteristics
| Prognostic factor | TNBC patient grouping based on PORT treatment
|
TNBC patients n=111 (100%) |
Non-TNBC patients cross-matching (n=111)a |
|
|---|---|---|---|---|
| PORT n=70 (63%) |
Non-PORT n=41 (37%) |
|||
| Age, years | 54±7 | 68±13 | 63±7 (range 28–81) | 60±11 |
| Pathology type | ||||
| IDC | 63 (90%) | 31 (76%) | 94 (85%) | 80 (72%) |
| ILC | 5 (7%) | 9 (22%) | 14 (13%) | 22 (20%) |
| Others | 2 (3%) | 1 (2%) | 3 (2%) | 9 (8%) |
| T stage | ||||
| T1 | 20 (29%) | 12 (29%) | 32 (29%) | 24 (22%) |
| T2 | 24 (34%) | 18 (44%) | 42 (38%) | 50 (45%) |
| T3 | 17 (24%) | 7 (17%) | 24 (22%) | 17 (15%) |
| T4 | 9 (13%) | 4 (10%) | 13 (11%) | 20 (18%) |
| Lymph node status | ||||
| N0 | 11 (16%) | 18 (44%) | 29 (26%) | 28 (25%) |
| N1–3 | 14 (20%) | 10 (24%) | 24 (22%) | 17 (15%) |
| N≥4 | 45 (64%) | 13 (32%) | 58 (52%) | 66 (60%) |
| AJCC stage | ||||
| I | 8 (11%) | 10 (24%) | 18 (16%) | 14 (12%) |
| II | 9 (13%) | 8 (20%) | 17 (15%) | 25 (23%) |
| III | 53 (76%) | 23 (56%) | 76 (69%) | 72 (65%) |
| Grade | ||||
| 1 | 10 (14%) | 14 (34%) | 24 (22%) | 19 (17%) |
| 2 | 33 (47%) | 11 (27%) | 44 (40%) | 35 (32%) |
| 3 | 27 (39%) | 16 (39%) | 43 (38%) | 57 (51%) |
| Surgery | ||||
| MRM | 38 (54%) | 29 (71%) | 67 (60%) | 67 (60%) |
| BCT | 32 (46%) | 12 (29%) | 44 (40%) | 44 (40%) |
| Chemotherapy | ||||
| Neoadjuvant | 35 (50%) | 16 (39%) | 51 (46%) | 33 (30%) |
| Adjuvant | 28 (40%) | 20 (49%) | 48 (43%) | 43 (39%) |
| None | 7 (10%) | 5 (12%) | 12 (11%) | 7 (6%) |
| Hormonal | 0 | 0 | 0 | 87 (78%) |
Note:
a
83 received radiation and 28 did not receive radiation (matching mainly done based on surgical type and stage).
Abbreviations: AJCC, American Joint Committee on Cancer; BCT, breast-conserving treatment; IDC, invasive duct carcinoma; ILC, invasive lobular carcinoma; MRM, modified radical mastectomy; PORT, postoperative radiotherapy; TNBC, triple-negative breast cancer.